SNCA and Parkinson disease: These medical genetic findings together with molecular and structural characterization of toxic alpha-synuclein aggregates and neuropathological evidence of alpha-synuclein accumulation in Lewy bodies has led to a wide-spread hypothesis that lowering alpha-synuclein levels could be of therapeutic benefit for PD and related alpha-synucleinopathies4.